UBX241220C3000
- 0.05
- 0.000.00%
Unity Biotechnology Newsroom
Rodman & Renshaw Maintains Unity Biotechnology(UBX.US) With Buy Rating, Cuts Target Price to $8
Unity Biotechnology Analyst Ratings
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Foselutoclax Trial Results and Strong Financial Position
HC Wainwright & Co. : The Unity Biotechnology (UBX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Unity Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target
Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment
HC Wainwright & Co. : The Unity Biotechnology (UBX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $10.00 to $8.00.
Unity Biotechnology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Unity Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $10 Price Target
Unity Biotechnology Analyst Ratings
Unity Biotechnology's Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy Rating
Analysts Offer Insights on Healthcare Companies: Unity Biotechnology (UBX) and Rockwell Med (RMTI)
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)
Unity Biotechnology (UBX) Receives a Buy From Mizuho Securities
Unity Biotechnology Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on Unity Biotechnology (UBX)
The Latest Analyst Ratings for Unity Biotechnology